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ABSTRACT  
With the advent of high throughput screening, drugs are emerging to be more lipophilic and less hydrophilic. Liquisolid Technology aims at 
solubility enhancement of such entities via cosolvency concept in a relatively minimalistic setup where there is no need of sophisticated 
machinery and is cost effective. It involves constituting a drug into molecular dispersion via a non-volatile solvent and then transforming it into 
a dry looking, free flowing compressible powder. This article aims at mapping Liquisolid Technology where its preparation techniques and 
potential applications are reviewed. An overview of the performance of Liquisolid in areas of dissolution enhancement, zero order release, 
photostability enhancement, liquipellets and its role in natural product formulations is recorded for a number of drugs. 
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1. INTRODUCTION 
A major reason for failure of new chemical entities in clinical 
development is due to their poor pharmacokinetics along 
with toxicity or failure to prove their efficacy at minor level. 
It is found that most of novel drugs after lead optimization lie 
in the BCS class 2 or 4 which means that they are poorly 
soluble in water or are practically insoluble. 1 The advent of 
sophisticated techniques such as High Throughput Screening 
has led to identification of large number of chemical 
compounds. These compounds though lack in optimum 
pharmacokinetics due to their high lipophilicity, less water 
solubility and high molecular weight as compared to 
conventional drugs. Hence these properties impede the 
viability of the chemical compound. In the High throughput 
screening discovery technique, ‘the rule of 5’ states that poor 
absorption or permeation occurs when there are more than 
5 H-bond donors, 10 H-bond acceptors, molecular weight is 
greater than 500 and the calculated Log P (CLogP) is greater 
than 5 (or MlogP>4.15). High throughput screening lead 
compounds tend to have higher molecular weight and log P 
and lower aqueous solubility than conventional drugs. 2 It is 
practically impossible to step back to lead compound 
optimization phase of the drug & change its chemical 
structure just to enhance its physicochemical properties as 
required because of the enormous time and money already 
spent upon the novel agent development process. It costs 
anywhere near to 0.8-1.2 billion US Dollars and 10-15 years 
to launch a novel drug entity in market. Hence it isn’t a 
reasonable and viable option to send the drug back to lead 
optimization phase. Here formulation development plays a 
significant role in such cases to establish an optimum 
pipeline for drug delivery. 3 
This article is based upon one such formulation development 
technique viz. Liquisolid technology for improving the 
dissolution rate and bioavailability 4 of poorly water soluble 
or practically insoluble drugs. 
2. THEORY OF LIQUISOLID SYSTEMS 
Liquisolid Systems are free flowing, compressible 
admixtures of drug solutions or suspensions. It literally 
consists of words ‘liqui’ meaning Drug Solutions or 
Suspensions and ‘solid’ meaning in a powdered form. 
Liquisolid Systems aims at enhancing the water solubility 
and in-vitro dissolution of poorly water soluble drugs 
belonging to BCS class 2 and 4. It utilizes Co-Solvency 
concept for solubility enhancement of the subjected chemical 
entity. It is based upon incorporation of water insoluble drug 
into a Non-Volatile solvent in which the respective drug is 
fairly soluble and converting the resultant liquid drug 
solution or suspension into a free flowing and readily 
compressible powder by using carriers with high specific 
surface area, porous material and high liquid absorbing 
capacity and nanometric (10nm-5000nm) sized coating 
materials showing high surface adsorption. 5 Drug Solutions 
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or Suspensions mean drug of choice suspended into a 
suitable Non-Volatile solvent. Liquisolid systems are 
molecularly dispersed admixtures of such drug solutions or 
suspensions; hence they are dry-looking admixtures and are 
not exactly devoid of any moisture. Liquisolid compacts refer 
to compression of such admixtures into a unit dosage form. 
In order to achieve this, ‘flowable liquid-retention potential’ 
(Φ) & ‘compressible liquid-retention potential’ (Ψ) values of 
carrier and coating materials are screened by Liquisolid 
Flowability Test (LSF) & Liquisolid Compressibility Test 
(LSC) respectively. These values determine the ability & 
quantity required of carrier and coat to retain its 
compressibility and flowability while equipped with certain 
amount of Liquid drug solution or suspension. 5-6 Comparison 
between Coarse, Amorphous and Molecular Dispersions is 
shown in Figure 1 out of which liquisolid systems are 
molecular dispersions of drug in solvent. 
 
 
Figure 1: Difference between Coarse, Amorphous and Molecular Dispersions (Adapted from 57) 
 
2.1 Building Blocks for LiquiSolid Systems 5 
1. Non-Volatile Solvent– Water Miscible Solvents are 
selected in which the subjected water insoluble drug can be 
incorporated and shall be readily soluble or suspendable. 
The resultant Drug Solution/ Suspension should be orally 
safe. High Liquid Concentration has proved to enhance 
dissolution of the drug and low concentration is known to 
prolong the effect of the drug. Some Examples are 
Polyethylene Glycol 20011,12,17,37, Polyethylene Glycol 30024, 
Polyethylene Glycol 4009,20,25, Polyethylene Glycol 60017, 
Polysorbate 20 (Tween 20)33,Polysorbate 80 (Tween 
80)13,14,25,28,31,32,39, Propylene Glycol8,10,14,15,19,22,30, Glycerin33, 
Cremophor® EL (Polyoxyl 35 Castor Oil)20,23,39, Synperonic® 
PE/l61 (Poloxamer 181)20,29,37, Labrasol25,56, Kollicoat® 
SR30D23,29 , Transcutol® (Diethylene Glycol monoethyl 
ether)25,39, Capryol™ 9029,56, Solutol® HS1529, Capmul® PG8 
(Propylene glycol mono caprylate)39 
Polysorbate 80 is such a solvent which was primarily used 
for retarding the drug release owning to the fact that most of 
the drugs have the lowest solubility in Polysorbate 80 but 
still higher than that of water making it an excellent 
retardant along with a matrix forming agent such as 
Eudragit® or Hypromellulose polymers. 
2. Carrier- Porous materials having high specific 
surface area & liquid absorption capacity can be employed 
as carriers which can absorb the resulting Drug Solution to 
convert it into a dry looking free flowing powder. Some 
examples are Microcrystalline Cellulose ( Avicel PH 101, 102, 
200)8-13,19-23,27,30-33, Amorphous Cellulose, Ethyl  Cellulose28, 
Dibasic Calcium Phosphate, Fujicalin® (Synthetic Dibasic 
Calcium Phosphate Anhydrous)21, Neusilin® US2 (Synthetic 
Amorphous Aluminometasilicate)21,46,56, Eudragit® (RL, 
RS)14,28,31,33, HPMC K4M (Hydroxy propyl ethyl cellulose)33, 
Starch26, Lactose12,27,34, Mannitol34 and Florite® (Calcium 
Silicate)21. 
Microcrystalline Cellulose is the pioneer carrier used in the 
Liquisolid technique as almost used in every initial research 
involving Liquisolid technique. Though over the time many 
have exploited other carriers in the search of better surface 
exposure of the drug to the dissolution media. Javadzadeh 
et al. reported comparison between different grades of 
Avicel® (Microcrystalline Cellulose) and its effect upon 
the ultimate formulation. Avicel® 101 proved an increase 
in the flowability of the Liquisolid admixture. Avicel® 101 
and Avicel® 102 showed an enhanced dissolution profile 
of the drug piroxicam in the same experiment. Avicel® 
101 & Avicel® 200 produced hard compacts as compared 
to Avicel® 102. Hence Javadzadeh et al. concluded that 
Avicel® 101 to be an optimum grade of Microcrystalline 
Cellulose. 16 
Specific Surface area (SSA) of the powder ultimately 
decides the amount of wettability and surface exposure of 
the drug particles with the dissolution media. Hence it is 
essential to select a carrier which has a high Specific 
Surface area. Nokhodchi et al. reported surface areas of 
various carriers screened by BET Surface area method which 
are enlisted in Table 1. It was concluded that Neusilin® US2 
increases the liquid load factor of the powder blend by a 
factor of 7 due to its extremely high SSA. Hence Neusilin® 
US2 holds immense potential in not only obtaining a 
proficient dissolution profile but also in high dose 
incorporation for Liquisolid technology which is often 
limited by the low liquid absorption capacity of 
Microcrystalline Cellulose and other such carriers. 21 
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Table 1: Surface areas of various powders used as carriers in Liquisolid System 
Carrier BET Surface Area (m2/g) 
Fujicalin® (Synthetic Dibasic Calcium Phosphate Anhydrous) 32 m2/g 
Avicel® PH200 (Microcrystalline Cellulose) 1 m2/g 
Florite® (Calcium Silicate) 142 m2/g 
Neusilin® US2 (Synthetic Amorphous Magnesium Aluminometasilicate) 339 m2/g 
 
3. Coat- Materials having very fine particle size and a 
highly adsorptive surface are used to adsorb any excess 
liquid and to seal and coat the carrier particles. A desired 
particle size range of these adsorptive particles is 10nm-
5000nm 5. Amorphous Silicon Dioxide (Aerosil 200, Cab-O-
Sil® M5) is used widely as it fits best in the desired 
properties of the coat 5, 8-13, 19-23, and 30-32. Neusilin® US2 has 
been experimentally tried to serve a dual purpose of carrier 
and coat as well which resulted in a better flowability of the 
admixture 21. Neusilin® US2 is also being used as both 
carrier as well as coat in the authors research on Liquisolid 
systems and preliminary results has shown a significant 
enhancement of Liquid load factor due to enhanced 
flowability Unpublished Data. Mesoporous Silica was 
screened by Chuanbin et al. which indicated a huge BET 
surface area of 1030 m2/g and pore size of 2.8 nm thus 
promising a high liquid adsorption capacity as compared to 
conventional silica 26. 
4. Adjuvants- Binders, Lubricants, Diluents, 
Disintegrants, Matrix forming polymers can be added as per 
requirement and can be blended with the parent 
preparation. 
Super Disintegrants serve an instrumental role in Liquisolid 
systems to force open the tablet for disintegration due to the 
fact that it may be unable to do so without a disintegrant due 
to high amount of Non Volatile solvent concentration in the 
dry looking powder. Sodium Starch Glycolate is used 
extensively as a superdisintegrant in the Liquisolid 
Formulations 8-10, 13, 19, and 32. Maize Starch 20 and 
Crosspovidone 39 were also reviewed as used in the same as 
Disintegrants. Vraníkova et al. reported effects of various 
superdisintegrants upon the liquisolid compacts of 
Rosuvastatin which stated Crosspovidone to be the most 
suitable disintegrant and a binary mixture of Crosspovidone 
and Sodium Starch Glycolate suitable for tablet 
disintegration enhancement 43-44. However, Sodium Starch 
Glycolate still remains the popular choice of disintegrant in 
most of the formulations. 
Lubricants can be used as required but are a major missing 
from most of the Liquisolid formulations as the flowability is 
already achieved as desired in precompression phase of the 
Tablets. Though some research has reported the usage of 
Magnesium Carbonate 11, Magnesium Stearate 28 and Talc 28. 
2.2 Scheme of Preparation of Liquisolid Systems 
Most of the Liquisolid systems have been prepared 
according to the original scheme and method as reported by 
Spireas S 5. Figure 2 explains the various steps required to 
formulate Liquisolid systems. 
 
 
Figure 2: Scheme of Preparation of Liquisolid Systems 
Phase 1 (Drug Solutions or Suspensions): Mix 
Drug + Non Volatile Solvent & heat to 80oC - 90oC 
with constant stirring until homogeneous drug 
solution obtained 
Incorporate resultant hot liquid 
medication in calculated quantities of 
Carrier followed by 3 stages of mixing 
M1: Blend at 1 
rotation/second for 1 
minute avoiding excessive 
trituration 
M2 (Wet Particles): Spread 
the admixture evenly as a 
uniform layer on mortar 
surface. Allow to stand for 5 
minutes 
M3 (Liquisolid System): 
Scrap the powder & blend 
with Coating Particles 
Add Adjuvants as per as 
necessity and blend for 30 
seconds 
TABLETTING, ENCAPSULATION OR 
PELLETIZATION 
•For Tabletting:- Compress at Specific 
Crushing Strength = 15kg/gm 
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Also, over the time many process developments were also 
recorded to achieve some enhanced results from the parent 
scheme. There are two such developments achieved which 
has reportedly enhanced the Liquid Load factor and 
dissolution profiles of resulting experiments. 
1. Addition of binders at Phase 1 in Drug solutions or 
Suspensions in order to achieve an improved dissolution 
profile. Polyvinylpyrrolidone (PVP), Hydroxypropyle 
Methylcellulose (HPMC) and Polyethylene Glycol (PEG 
35000) were investigated for the same where PVP as binder 
significantly enhanced the dissolution profile of drugs viz. 
Carbamazepine 12 and Glyburide 27. 
2. Wet Granulation of the final Liquisolid admixture 
using binders viz. hydroxypropylethylcellulose 14, acetonic 
solution 21 and water 38. Since wet granulation involves 
drying of the entire powder mixture after granulation, it 
compromises the basic philosophy of Liquisolid admixtures 
to create Microsystems or molecular dispersions as such 
intense heat after granulation process can also evaporate the 
Non Volatile solvent in the liquid medication. The above 
experiments were successful in retarding the drug release of 
Propranolol Hydrochloride 14, enhancing drug release of 
Tocopherol Acetate 21 and Norfloxacin 38 with addition to 
enhancement in liquid load factor when water used as binder 
which is attributed to water being able to create wider 
spaces between the structures 38.  
3. MATHEMATICAL MODEL EMPLOYED TO 
CALCULATE LIQUID LOAD FACTOR OF EXCIPIENTS 
5 
These equations were originally introduced by Spireas S. in 
order to calculate the quantities of carrier and coat required 
to convert the liquid medications into a dry looking free 
flowing and compressible compacts. The equations are 
enlisted below. 
LfΦ (Liquid Load for acceptable Flowability) =   
  
 
 (1) 
where Φ is the flowable liquid-retention potential of Carrier 
& φ of the Coating material respectively. 
LfΨ (Liquid Load for acceptable Compressibility) =     
 
 
  
(2) 
where Ψ is the compressible liquid-retention potential of 
Carrier & ψ of the Coating material respectively. 
R is the ratio of Carrier and Coating material to be used 
expressed as  
R = 
                  
               
  (3) 
Lf0 (Optimal Liquid Load Factor) = LfΦ if LfΦ < LfΨ (4) 
Lf0 (Optimal Liquid Load Factor) = LfΨ if LfΨ < LfΦ (5) 
Similarly weight of Carrier & Coat can be calculated by the 
following expression;  
Lf0 (Optimal Liquid Load Factor) = 
                              
                 
 
(6) 
Hence, Q = 
  
   
 (7) 
Since (6); q = 
 
 
 (8) 
4. DETERMINATION OF Φ (FLOWABLE LIQUID 
RETENTION POTENTIAL) & Ψ (COMPRESSIBLE 
LIQUID RETENTION POTENTIAL) VALUES 5 
It is evident that a powder certainly retains only a limited 
amount of liquid medication while maintaining an acceptable 
limit of flowability and compressibility. Hence, established 
mathematical models are used to calculate the amount of 
liquid the powder can be loaded with resulting into an 
acceptably free flowing and readily compressible ‘dry 
looking powder’. This parameter is known as Liquid Load 
Factor (Lf). In order to calculate an optimal Lf, it is necessary 
to determine ‘flowable liquid-retention potential’ (Φ) & 
‘compressible liquid-retention potential’ (Ψ) values of 
carrier and coating materials respectively. They are 
determined by Liquisolid Flowability Test (LSF) &Liquisolid 
Compressibilty Test (LSC). 
4.1  Liquisolid Flowability Test (LSF) 
LSF experiment aims at screening the flow property of the 
powder and capping a limit to liquid load factor as required 
by the researcher. Hence, this technique not only serves 
viable for Liquisolid systems but also for regular testing of 
flow properties of powder with excellent reproducibility. The 
flow property can be tested by number of different 
experiments such as by a Recording Powder Flowmeter 5, 
Angle of Slide 6 or by simple Angle of Repose experiment as 
per the suitability and performability of the experiment. The 
technique offers flexibility to decide optimum flow as 
required hence producing variable results for different 
researchers due to the independency of parameters decided 
by them. A schematic representation of the LSF is made in 
Figure 3. 
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Figure 3: Scheme of Liquisolid Flowability Test (LSF) 
 
4.2 Liquisolid Compressibilty Test (LSC) 
LSC experiments aims at recording the maximum liquid 
retention possible in order to produce compacts with 
maximum hardness. Though if compacts are compressed at 
maximum hardness, they tend to create fragments or not 
disintegrate at all in the In-Vitro Dissolution study as 
recorded by the author unpublished data. Hence, in 
maximum researches in Liquisolid technology, it is no where 
reported that the LfΨ was considered over LfΦ due to the fact 
that most of the carriers can hold enormous amount of liquid 
if they are just to be compacted at their plateau strength and 
LfΨ values are always way higher than the LfΦ values. Still it 
is a suitable way to demonstrate the capability of the powder 
to retain the liquid while producing acceptable compacts. If a 
slight modification is done for the experiment suggesting 
compression at desired hardness over compression at 
plateau strength, the technique can prove its viability and 
can provide with better comparisons between Φ & Ψ values. 
A schematic representation of the LSC is made in Figure 4.
 
Powder systems having ratios as R1, R2, R3.. Rn are prepared using desired carrier and coat material. Suitable 
weight of each powder system was prepared sufficient for further analysis. 
Liquid/Powder admixtures having ascending Lf vaules were prepared as Cw in quantities corresponding 10 
grams of carrier and coat as per R value; For Example- 
•For R=10 :- Cw1= 0.1 Lf; Since Lf= W/Q , W(Weight of Non-Volatile Solvent) = 1 gram for 10 gram of Powder 
admixture. 
•Similary Cw2, Cw3, Cw4, Cw5 & Cw6 having Lf values of 0.2, 0.3, 0.4, 0.5 & 0.6 respectively were prepared for all 
the three Carrier:Coat ratios. 
Assess the Flow rate of every admixture by any desired process established (Methods such as Angle of Repose, 
Angle of Slide, Powder Flow Tester experiments are recorded in literature) 
Select a Lf value for each Ratio value which complies to the preselected limit of acceptable flowability 
Plot the selected optimum Lf values against their respective reciprocal values of R (Carrier:Coat Ratio) 
Calculate the Polynomial equation for the above plot. (y=mx+c) 
y= LfΦ  
Slope(m)= Flowable liquid-retential potential of coat (φ) 
Intercept(c)= Flowable liquid-retential potential of carrier (Φ) 
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Figure 4: Scheme of Liquisolid Compressibility Test (LSC) 
 
5. CHARACTERIZATION PARAMETERS 
5.1 Solid State Characterization 
It involves Drug-Excipient incompatibility studies, 
Crystallinity determination and morphology studies of the 
Liquisolid admixture. 
5.1.1 Fourier Transfer Infrared Spectroscopy 22, 29 
It is performed for all the excipients and liquisolid mixtures 
to find out whether if there are any visible chemical 
interactions. KBr pellet method is widely employed for the 
same where substance under investigation is compressed 
into a pellet at the ratio of 9:1 to 99:1 as required and is 
compressed under a hydraulic press under a force of 8-10 
ton. Some results from the literature are reviewed for the 
same. Reports extensively record presence of same peaks in 
the liquisolid formulation same as the other congeners 
inferring no possible interactions between the excipients and 
Powder systems having ratios as R1, R2, R3.. Rn are prepared using desired carrier and coat material. Suitable weight of each 
powder system was prepared sufficient for further analysis. 
Liquid/Powder admixtures having ascending Lf vaules were prepared as Cw in quantities corresponding 10 grams of carrier 
and coat as per R value; For Example- 
For R=10 :- Cw1= 0.1 Lf; Since Lf= W/Q , W(Weight of Non-Volatile Solvent) = 1 gram for 10 gram of Powder admixture. 
Similary Cw2, Cw3, Cw4, Cw5 & Cw6 having Lf values of 0.2, 0.3, 0.4, 0.5 & 0.6 respectively were prepared for all the 
three Carrier:Coat ratios. 
Compress tablets  from each resulting admixture at plateau compression force 
Calculate Pactisity (Ω) = Hardness of Tablet (kg/cm2) / Weight of Tablet (gm) 
To calculate Characteristic Intrinsic Pactisity (Ω0) and Sponge Index (σi) plot log Ω on y axis versus Cw concentrations on x 
axis where Cw= Liquid Weight / Powder Weight 
Calculate the Polynomial equation for the above plot. (y=mx+c) 
Slope(m)= Modulus of Sponge Index l σi l 
Intercept(c)= Intrinsic Pactisity (Ω0) 
Calculate Ψmix = (log Ω0 - log 20) / σi for all the Ratio (R) values 
Calculate LfΨ = Ψmix (1) + (1/R) for all the R values 
Plot the selected optimum Lf values against their respective reciprocal values of R (Carrier:Coat Ratio)  
Calculate the Polynomial equation for the above plot. (y=mx+c) 
y= LfΨ 
Slope(m)= Compressible liquid-retential potential of coat (ψ) 
Intercept(c)= Compressible liquid-retential potential of carrier (Ψ) 
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the drug. 22, 29 One report suggested the liquid vehicle 
forming hydrogen bonds with the drug, which majorly thus 
contributes to solubility enhancement which was thence 
attributed to the shift in peaks of the liquisolid formulation 
as compared to the drug. It also reported no difference 
between the spectra of fresh and aged liquisolid formulations 
confirming the stability of the formulation under stressed 
humidity conditions. 29  
5.1.2 X-Ray Diffractometry 12, 14, 31 
Powder X-Ray Diffraction graphs are widely studied with a 
perspective of comparison of drug, excipients and the 
resultant liquisolid formulation in order to keep a check 
upon the crystallinity of the formulation and its role in 
solubility enhancement of the drug. The samples are exposed 
to Cu Kα radiations where they are screened for 2θ range 
upto 80º. Reports were made where no loss in crystallinity of 
the powder was demonstrated being attributed to particle 
size reduction in process for the drug and the presence of 
peaks resulting from microcrystalline cellulose in that study. 
12, 22 Although maximum reports demonstrated an 
attenuated crystallinity where the flattening of the graphs 
were observed which was inferred by reasoning that either 
the drug reached an amorphous state where it is relatively 
more soluble, solubilization of drug in liquid vehicle or was 
inferred upon low drug concentration in the final 
formulation. 14, 31 
5.1.3 Scanning Electron Microscopy 29, 31 
SEM experiment offers a great perspective upon the changes 
in the microenvironment and possible permutations of the 
formulation. Maximum studies have reported the 
disappearance of the crystallinity of the drug where mostly 
no drug crystals are observed for liquisolid formulations 
which is attribute to the super porous structure of the carrier 
that the drug which is a part of a microsystem as a molecular 
dispersion gets included and incorporated into the carrier 
matrix thus rendering the drug visually unconceivable. 
5.1.4 Differential Scanning Calorimetry 17, 29, 61 
This technique is the most favourable one where drug-
excipient incompatibilities are concerned. It provides a 
perspective of comparision in the enthalpy changes of the 
drug and excipients. In a DSC sample holder 1-2 mg of 
sample under investigation is weighed. The sample pans are 
hermitically sealed and then are subjected to heat-flux DSC in 
the temperature region of anywhere from 30°C-300°C , with 
a heating rate as required and in an atmosphere of flowing 
nitrogen. The following determinations are carried out: - 1. 
The active drug substance and the excipients individually. 2. 
Physical mixture of drug and excipients 3. Optimized 
liquisolid formulation. The changes in the graphs are 
observed to draw out inferences for any incompatibilities. 
Reports record no possible interactions between drugs and 
excipients due to their inert nature although a vast majority 
of results have reported a slight attenuation of the sharp 
peak resulting in a peak with curvature attributing to loss of 
crystallinity of the drug. 
5.2 Experiments involved in LSC and LSF 
5.2.1 Operations involved in for flowability testing 
(A) Carr’s Index and Hausner Ratio 62 
Flowability of all liquisolid formulations and physical 
mixtures is assessed by determination of Carr’s Index (CI) 
also known as percentage compressibility. The CI was 
calculated from the poured and tapped densities. The CI is 
calculated according to the following equation 
 CI% = 100  
                            
              
   (9) 
Hausner Ratio =  
             
           
 (10) 
Carr’s index and Hausner ratio inferences are enlisted in 
Table 2 
Table 2: Relationship of Carr’s Index and Hausner ratio with 
powder flowability 
Carrr’s Index Flow property Hausner ratio 
≤10 Excellent  1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passsable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very very poor >1.60 
 
(B) Angle of Slide 6 
10 grams of Powder of investigation is placed on the lateral 
end of a polished aluminium plate and then the plate is lifted 
on its vertical axis until the powder aggregate slides down 
and that at that point, theta is recorded up from the ground 
considered as angle of slide. 33 degrees is considered 
optimum and acceptable angle for the liquisolid powders. 
(C) Angle of Repose: 64 
For the determination of the angle of repose, a wide-opening, 
glass funnel was secured with its tip at a pre-determined 
height above a sheet of paper placed on a horizontal surface. 
Twenty five grams of powder was allowed to slide slowly 
through the tip of the funnel resulting in the formation of the 
conical pile of powder. The angle of repose was calculated 
using the following relationship: 
     
 
 
  (11) 
 Where α is the angle of repose, and h and r are the height 
and radius of the base of the conical pile, respectively. A 
value of α < 30° indicates ‘excellent’ flow whereas α > 56° 
indicates very poor flow. The intermediate scale indicates 
good (α between 31 and 35°), fair (α between 36 and 40°), 
passable which may hang up (α between 41 and 45°), and 
poor which must be agitated or vibrated (α between 46 and 
55°) 
5.2.2 Operations involved in for compressibility testing 55 
(A) Walker Compressibility Coefficient, W 65 
The value of Walker compressibility coefficient, W, is 
determined by linear regression analysis by plotting the 
relative volume, V, of the compacts as a function of log 
compression pressure, log σc, according to Walker equation 
(Table 3). The value of compressibility coefficient, W, was 
determined from the slope of the straight line. The relative 
volume, V, of powder blend is calculated as the inverse of the 
relative density of the compact.  
(B) Kawakita Parameters, a and 1/b 66 
 The values of P/C are plotted as a function of compression 
pressure, P, according to the Kawakita equation (Table 3). 
The value of Kawakita parameter, a, is obtained from the 
reciprocal of the slope of the straight line and the parameter, 
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1/b, was calculated from the value of y-intercept, 1/ab, and 
parameter, a. 
(C) Mean Yield Pressure, Py 67 
The value of mean yield pressure, Py, is calculated from the 
inverse of the slope value, k, obtained from the linear 
segment of the plot of compact density vs. compression 
pressure data according to Heckel equation (Table 3).  
(D) Compactibility parameter, σ0, and Bonding capacity, b 68 
The values of compactibility parameter, σ0, and bonding 
capacity, b, are determined using Ryshkewitch-Duckworth 
equation (Table 3). The nonlinear regression analysis of the 
plot of tensile strength, σt, as a function of compact porosity, 
ϵ, yields intercept, σ0, which is tensile strength of the 
material at zero porosity and is indicative of compactibility 
of the powder material; the slope value of the plot represents 
the bonding capacity, b, of the powder material under 
increasing pressure.  
(E) Compactibility parameter, σtmax, and Compression 
susceptibility, γ 69 
By plotting tensile strength of the compacts, σt, and the 
product of compression pressure, σc, and relative density, ρr, 
of the compacts according to Leuenberger equation (Table 
3), the values of compactibility parameter or maximum 
tensile strength of the compacts, σtmax, and compression 
susceptibility, γ, are computed using nonlinear regression 
analysis.
 
Table 3: Mathematical models for compressibility and compactibility screening of liquisolid systems. 
Powder Property Model Equation Constants 
Compressibility Walker V = - W log  
σc + Vr 
W is Walker compressibility coefficient, and Vr is the initial relative 
volume of powder material at 1 MPa pressure 65 
Kawakita  
 
 
 
 
 
 
  
 
The value of Kawakita parameter, a, represents the engineering 
strain or the degree of volume reduction at maximum pressure 
(Cmax), and the value of 1/b represents the pressure to achieve an 
engineering strain of a/2 which can be correlated to the plasticity 
or as deformation capacity of the material 66. 
Heckel ln(
 
    
)= k 
 c + A 
1/k gives a material-dependent constant known as mean yield 
pressure, Py, which is the ability of the powder material to deform 
plastically under pressure 67. 
Compactibility Ryshkew
itch-
Duckwor
th 
σt = σ0 e-bε σt is the tensile strength of compact, σ0 is the tensile strength of 
compact at zero porosity, b is bonding capacity of powder particles 
under increasing pressure, and ε is porosity of the compact 68. 
Leunberge
r 
σt = σtmax (1- 
e-ᵞσcρr ) 
σtmax is the maximum tensile strength of compact at relative density 
(ρr 1), and γ is compression susceptibility that characterizes the 
deformation behavior of material 69. 
 
 
6. LITERATURE REVIEW 
6.1 In Dissolution enhancement 
Liquisolid Systems are widely entrenched as models of 
dissolution enhancement of poorly water soluble drugs. 
Since its inception in 1998, many researchers have 
repeatedly validated Liquisolid technology with respect to 
its solubility enhancement capacities and potential to be 
formulated as unit dosage forms. For majority of the studies, 
it has been probated that Liquisolid compacts enhance 
dissolution by Co-Solvency mechanism which results into 
formation of a molecular dispersion of the poorly water 
soluble drug material into a water miscible non volatile 
vehicle which thus improves the wettability of the drug. This 
improvisation of wettability can also be attributed to the 
carrier molecules carrying these molecular dispersions to 
the dissolution media which provides a high surface contact 
of drug with dissolution media owning to the high specific 
surface area (SSA) of Liquisolid carriers. Poorly water 
soluble drugs belonging to BCS Class 2 & 4 viz. Prednisolone 
8, Methyclothiazide 9, Piroxicam 13, Indomethacin 15, 
Famotidine 18, Carbamazepine 19, 26, Valsartan 22, 
Candesartan Cilexitil 32, Simvastatin 52 and Nimodipine 56 
demonstrated an excellent improvisation of dissolution 
profile with statistical significance as compared to their 
commercially available counterparts and directly 
compressed tablets. Even if all of them do not share a 
common non volatile solvent used for formulating liquid 
medications, a common thread is that every research listed 
above uses the solvent in which the drug shows maximum 
solubility. Hence it can be concluded that choice of solvent 
cannot possibly affect the dissolution mechanism if the 
choice of solvent is based upon maximum solubility of drug 
into various solutions. 8, 9, 13, 15, 18, 19, 22, 26, 32, 52, 56 
Similarly many other results were published with varied 
diaspora of findings which can lead to further prospective 
developments into the technique. Spireas S. et al. reported 
that drug release rates were independent of the volume used 
to simulate the GI fluid in In-Vitro dissolution testing in case 
of drug Hydrocortisone. Thus this study proved Liquisolid 
systems advantageous in actual variable physiological 
conditions where GI fluid constantly varies. This study also 
hints towards zero order release achievable by Liquisolid 
technique which was further confirmed by others. 10 
Javadzadeh et al. reported usage of Polyvinylpyrrolidone 
(PVP) as an additive in drug solutions which improved 
dissolution of Carbamazepine 12 whilst the same was 
confirmed by Singh et al. using PVP in drug solution of 
Glyburide 26. Cremophor® EL (polyethoxylated castor oil) 
was identified as a potentially viable solvent when it was 
formulated as Liquisolid systems having Naproxen 20 and 
Griseofluvin 23 as model drugs. They showed significant 
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improvement in dissolution profile as compared to their 
commercial tablets. Similarly Labrasol® was confirmed by 
Eztimibe Liquisolid systems 25 and Synperonic® PE/L-61 by 
Norfloxacin 37 and Spirolactone 29 where in case of 
Spirolactone Liquisolid systems, it additionally identified 
Capryol™ 90 & Synperonic® PE/L-61: Solutol® HS 15 as 
promising liquid vehicles. 
Results such as no statistical significance between 
commercial or conventional form and Liquisolid form of 
Famotidine was recorded although a visible difference in 
release pattern was prevalent due to rapid dissolution of the 
Liquisolid Compact as compared to the conventional tablet 
18. In case of Norfloxacin as reported by Suliman et al. the 
drug showed an unprecedentedly high dissolution with 
Synperonic® PE/L-61 as compared to Polyethylene Glycol 
200 contradicting the fact that Norfloxacin had a relatively 
low solubility in Synperonic® PE/L-61 as compared to 
Polyethylene Glycol 200. 37 Further research upon the same 
was elucidated by the author addressing the problem of low 
liquid load factor and inability of high dose incorporation. 
Hence the researcher tried to solve the same by Wet 
Granulation technique with the carrier material before it 
was subjected to exposure to hot liquid medication. The 
process allegedly resulted into creation of wider spaces 
inside the carrier structure ultimately enhancing the liquid 
load factor from 0.2 to 0.4 in case of Polyethylene Glycol 200 
and 0.14 to 0.29 in case of Synperonic® PE/L-61. There 
were no significant differences in dissolution profiles when 
compared with the liquisolid formulations without 
granulation hence ultimately proving the efficiency of the 
process. 38 
Neusilin® US2 was screened as carrier which bore 
astounding results as compared to the conventional carriers 
used previously for the same. Jadhav et al. reported a 
phenomenal enhancement of the liquid load factor to 1.25 
with Neusilin® US2 hence opening varied possibilities of 
high dose incorporation which was an initial drawback for 
the Liquisolid technique. Progesterone as a model drug was 
successfully formulated using Neusilin® US2 as carrier and 
showed improved dissolution as compared to conventional 
forms of the same. 46 Same was confirmed by Hentzschel et 
al. for Griseofluvin. 24 
In one of its kind, a different perspective upon the Liquisolid 
systems was perceived by Lu M. et al. where they employed 
Raman Spectroscopy in screening of Tadalafil Liquisolid 
systems which indicated loss in crystallinity demonstrated 
by alteration of intensity as compared to pure drug. It gives 
us an insight into amorphous conversions of drug molecules 
resulting into better aqueous solubility which was also 
confirmed by X-Ray diffraction studies. This study also 
proved the homogeneous distribution of the drug across the 
Liquisolid system demonstrated by even tone of the light 
intensity in the graph. 41 A different study employed mixed 
Co-Solvency technique where they recorded that upon using 
35% Sodium Caprylate, 5% Sodium Benzoate and 5% 
Niacinamide with Rifabutin followed by formulation of 
liquid medication by suspending it into Propylene Glycol, it 
showed a twofold dissolution enhancement as compared to 
in-house developed fast release capsules. It surprisingly 
showed no loss in crystallinity by X-Ray diffraction studies. 
51 
6.2 In-Vivo and Ex-Vivo performance of Liquisolid 
systems 
Liquisolid system has also proved itself in its In-Vivo 
performance enhancing oral bioavailability of poorly water 
soluble drugs. It was first confirmed by Khaled et al. where 
they recorded ~15% in-vivo oral bioavailability 
enhancement of Hydrochlorthiazide in Beagle dogs also 
entrusting a greater absorption rate as compared to the 
conventional tablets. It also identified its dissolution rate 
enhancement. This particular feature can be attributed to 
better wettability of drug due to liquisolid formulation. 11 
Badawy et al. identified and evaluated Mosapride Citrate’s 
simulated bioequivalence performance by using biorelevant 
media viz. 0.1N Hydrochloric Acid, A hypoacidic stomach 
model (pH 5 Acetate buffer), and a transfer model simulating 
intestinal transfer from pylorus. This model demonstrated 
successful prediction of in vivo behavior of the drug which 
was further confirmed by Human volunteer’s in-vivo study 
which indicated oral bioavailability of drug at Relative 
bioavailability of 121.2 % as compared to commercial 
tablets thus establishing the biorelevant model reliable for 
adaption in further research. 34 Oral Bioavailability 
enhancement was similarly recorded for Gliclazide35, 
Risperidone45 and Pioglitazone53 liquisolid formulations via 
in-vivo experiments. Permeation enhancement was 
demonstrated by experiments conducted by Sanka et al. 
where they not only recorded enhanced in-vitro dissolution 
for Clonazepam, but also confirmed the potential of 
permeation enhancement by liquisolid system of 
Clonazepam which demonstrated enhanced permeation in 
diffusion studies. Although clonazepam is highly lipophilic, 
hence permeation enhancement can also be attributed to its 
natural property and also to the fact that since it was a ex-
vivo experiment, higher concentration in diffusion media 
may have resulted into enhanced permeation due to 
solubility enhancement of clonazepam. 36 Similarly the same 
inferences were drawn out for Raloxifene HCl which 
demonstrated 2 fold ex-vivo intestinal permeation 
enhancement. 39 
6.3 In Sustained Release Formulations 
Although liquisolid systems are majorly substantiated for 
dissolution enhancement purposes, many have tried 
identifying their suitability for retarding the release of some 
drugs. Out of which the very first cofirmation was laid by 
Javadzadeh et al. where they recorded an optimal 
retardation and better dissolution profiles of Propranolol 
Hydrochloride by using Eudragit® RL as carrier. 14 
Nokhodchi et al. reported same for Theophylline using 
Hydroxypropylethylcellulose additionally with Eudragit® 
RL & RS with its synergistic action retarded the drug release 
more than without HPMC due to matrix formation. 17 
Trimetazidine Hydrochloride was formulated as sustained 
release tablets using Tween® 80 as Non Volatile solvent and 
Eudragit® L100 as matrix forming agent. It confirmed a 
prolonged release of the drug. 28 Venlafaxine Hydrochloride 
as a model drug was formulated using Tween® 80 as Non 
Volatile solvent and Eudragit® RS & HPMC respectively as 
matrix forming agent which showed sustained release of 9 
hours in case of Eudragit® RS and 12 hours for HPMC 
respectively. It can thus be understood that HPMC highly 
retards the drug release due to its hydrophobic nature. 31  
6.4 Photostability 
Number of drugs upon exposure to light loses their potency 
due to photodegradation which also may result into toxic 
rendering of drugs. Hence, applicability of this technique 
was exploited to conclude whether if it can produce better 
results as compared to conventional formulations. Khames 
et al. evaluated the photostability of Amlodipine liquisolid 
tablets and conventional tablets were tested according to 
ICH- Q1B guidelines. Titanium Dioxide and Silicone Dioxide 
were used as coating materials in ratios of 1:1 and 2:1. The 
tablets were irradiated with varied light sources as specified 
in the ICH guidelines for eight hours. The liquisolid tablet of 
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Amlodipine not only resulted in enhanced dissolution but 
also proved the applicability of the technique in protection 
of photosensitive drugs where drug retention in liquisolid 
tablet was recorded at 97.37 % as compared to 73.8 % of the 
conventional tablet of Amlodipine after irradiation (P<0.05). 
Also an inverse proportionality was recorded between 
photoprotective effects of liquisolid systems with respect to 
the carrier: coat ratio (R). Though a fact cannot be 
overlooked that only one study in this domain has been 
conducted in the 22 year old history of Liquisolid Systems 
thus owning a future prospective for study of its 
photoprotective effects. 30 
6.5 Zero Order Release 
Although Propranolol Hydrochloride is a BCS Class 1 
drug, it differs if the conventional matrix type approach is 
compared with liquisolid approach in which both 
relatively sustain the release of the drug but liquisolid 
technology has a plus point of achieving a near zero order 
release which is much acceptable and desirable than the 
first order release of the conventional matrix type tablet 
approach. 14 The same near zero order release was also 
achieved by Syed et al. for Trimetazidine Dihydrochloride. 
28 Thus these results establish the application of the 
liquisolid technique for achieving zero order release. 
6.6 Usage of Natural polymers and in Herbal 
Formulations 
Application of liquisolid technology upon herbal origin 
entities was first pioneered by Sharma et al. 2016 where 
they formulated poorly soluble curcumin which also has a 
very low oral bioavailability. Curcumin was selected as a 
model drug, Polysorbate 80 was selected as non volatile 
solvent, Avicel® PH 102 as carrier and Aerosil® as coat 
respectively. The results indicated a greater enhancement in 
magnitude of drug release of liquisolid tablet as compared to 
conventional tablets at any given time point. Liquisolid 
tablets of curcumin achieved 100% release within two hours 
as compared to 89.2% of conventional tablets without 
liquisolid microsystem. Ex-vivo permeation studies were 
carried out on gastric mucosa of New Zeland rabbits where 
also enhanced permeation was observed. In-vitro 
cytotoxicity was screened in n87 cancer cells to find out the 
differences between activity of the new formulation. A slight 
lower cytotoxicity was observed for liquisolid tablet as 
compared to pure curcumin which can be attributed to 
presence of excipients. In-vivo studies conducted in ravvits 
indicated an amazing 15.4 folds enhancement of cmax and 
8.28 folds enhancement of absorption rate constant (ka) and 
18.6 folds enhancement of relative bioavailability of 
curcumin which can be attributed to the enhanced release of 
the drug due to co-solvency by liquisolid technology. 40 
Oregano essential oil via its powder extract was formulated 
into liquisolid and was directly compared to a freeze dried 
counterpart of it. Rosmarinic acid and Cavacrol are its active 
constituents which are poorly soluble due to which it has the 
potential to act as a model drug for liquisolid technology. 
70% Ethanol with 30% Glycerol was used as cosolvent due 
to extraction constraints of the drug and Neusilin® US2 as 
carrier was selected for liquisolid formulation. Ethanol was 
evaporated in due process. For freeze dried particles of the 
model drug, oregano powder extract was suspended in 
ethanol and then ethanol removal was induced by Rotary 
evaporator further hydration of film and freeze drying the 
mixture at -80°C overnight. Quantitative analysis was 
performed using UPLC. Dissolution enhancement was 
achieved by 2.2-2.8 times for Rosmarinic acid and 2.9 times 
for Cavacrol thus establishing the technique’s applicability 
for herbal extracts containing essential oils. 47 Similarly 
Curcuma comosa, a thai herb having estrogenic like action 
was also constituted as liquisolid by using Propylene Glycol 
as cosolvent, microcrystalline cellulose as carrier and 
colloidal silica as coat. Polyvinylpyrollidone was used as an 
additive. The herb’s active constituent was extracted by 
maceration. Dissolution enhancement was clearly recorded. 
This study introduced the potential of liquisolid tablets for 
formulation of viscous and oleoresins like natural crude 
extracts. 48 
Pathak et al. 2019 presented a path breaking study upon 
potential usage of many natural origin gums as matrices and 
carriers for liquisolid technology by modifying them as 
needed. This study indicated usage of modified 
polysaccharides as potential carriers which was achieved by 
modifying the natural gums viz. Tamarind kernel powder, 
Guar gum and Locust bean gum. Modification was achieved 
by a process where the raw powders were first suspended in 
water and were allowed to swell overnight which was 
further dried via evaporation leaving a highly porous 
structure. These treated powders were co-ground with 
mannitol (1:1) in order to achieve a better flowability of the 
gums. These modified polysaccharides were screened for 
particle size by Diffuse reflectance spectroscopy and for 
Specific surface area via Gas adsorption technique further 
equating with BET equation. Results were observed which 
proved the treated modified powders as optimum fot 
liquisolid systems as particle size was exponentially reduced 
for modified powders and SSA increasing by 359.3%, 
425.53% and 384.39% respectively for modified Guar gum, 
Tamarind kernel powder and Locust bean gum. Also even 
size distribution was observed inferred by lowered span 
values of modified powders. To screen these new powders 
Paclitaxel was used as a model drug to be incorporated into 
them with Solutol HS15® as cosolvent. Dissolution 
enhancement was observed as compared to conventionally 
compressed tablet. Ex-vivo permeation enhancement of 
61.59% was recorded for optimized liquisolid batch. A 
remarkable enhancement of IC50 cytotoxic potential of <20 
mmol/L was observed for NCL-N87 along with high cell 
death values in early and late apoptosis compared to 
conventional tablet (P<0.05). Oral bioavailability 
enhancement of 5.43 times was observed. This can also be 
attributed to the fact that due to enhanced release, much of 
drug was available for the system to be absorbed. Thus this 
study proved the applicability of the natural polymers for 
liquisolid technology. However a clear distinction was not 
made in the study indicating the merits of these modified 
polysaccharides upon the conventionally employed carriers 
for liquisolid technology. 54 
6.7 Liquipellet! Is it really novel? 
A study titled liquipellet was initially pioneered by Pezzini et 
al. 2016 where they introduced a new concept of liquipellet 
which addresses the loopholes of poor flowability and 
compactibility of liquisolid admixtures. It was developed 
primarily to enhance the liquid load factor along with the 
flow and compressible properties of the liquisolid 
microsystems. This study aimed at investigating liquipellet’s 
feasibility for felodipine. Cremophor® EL was used as 
cosolvent, microcrystalline cellulose as carrier and 
crosspovidone as coat. It created soft and porous structures 
which were further pelletized via Extrusion-Spheronization 
process where the admixture was wetted with 1% 
crosspovidone w/v in water and was further dried in 
fluidized bed. It was compared with conventional pellets 
without liquisolid microenvironment resulting into 
enhanced dissolution. Although no comparison was made 
with liquisolid tablets to prove the viability of liquipellet. 
Also since they claimed usage of crosspovidone for first time 
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as a coat, it was not compared with any of the conventionally 
used coating materials such as colloidal silica. 42 Later 
studies expanded and cleared upon the scope of liquipellet 
where Nokhodchi et al. 2019 addressed high dose 
incorporation and poor flowability and compressibility as 
inspiration for liquipellet where they formulated liquipellet 
using Naproxen as model drug. Tween® 80 and Kolliphor® 
EL were used as solvents, Avicel® PH101 as carrier and 
Aerosil® 300 as coat. Significant dissolution enhancement 
was observed along with a high Lf of 1. Due to enhanced 
flowability resulted by pelletization, Lf increases 
significantly allowing high dose incorporation. 60 Pezzini et 
al. reported ritonavir as model drug for liquipellet where 
significant Lf enhancement was achieved at 1.52 for 100 mg 
dose of drug which is rare for incorporation in conventional 
liquisolid admixtures. Dissolution efficiency (DE60min) 
enhancement was observed at 1.7 times and 8.29 times as 
compared to Ritonavir polymorph 1 & 2 respectively. 
Excellent flow properties and narrow size distribution was 
achieved due to pelletization. 58 Although this technique was 
purported as novel in the titles of these studies, the only 
novelty which stands here is the problem solving mechanism 
of this study related to conventional liquisolid admixtures 
which have deficiencies in flowability and compressibility. 
Liquipellet formulation overcomes this problem by 
pelletization of the conventional liquisolid admixtures. 
Hence, it is relatively nefarious to brand the technique as 
completely novel as it is mostly based upon the original 
work of Spiridon Spireas of methods of preparation of 
liquisolid systems. 5 
6.8 Stability Considerations 
A major concern about liquisolid technology revoloves 
around presence of solvents in a molecular dispersion form 
which invites prospectus to microbial growth, 
contamination or even degradation of product which can 
result into loss of activity. Hence, stability studies were 
conducted through various studies where all of them 
reported no loss in drug activity or form after prolonged 
periods of time. Trimetazidine dihydrochloride liquisolid 
tablets were subjected to accelereated stability studies for 6 
months at 40 ± 2ºC/75 ± 25% RH where the drug content 
was as 96.75 ± 0.12% at the end of 12 h of dissolution 
testing. The percentage of TZH released from the optimized 
formulation before storage was 81.56 ± 0.49%, where post 
stability study release was 82.45 ± 0.44%. Hence, it can be 
inferred that there was no significant loss in activity of the 
drug. 28 Similarly Mosapride citrate liquisolid tablets were 
evaluated for accelerated stability studies at 40 ± 2ºC/75 ± 
25% RH according to ICH guidelines 2003 for 3 and 6 
months respectively. Similarity factor for drug dissolution 
profiles compared to fresh tablets was 84.812 and 68.07 
after 3 and 6 months respectively. 34 Venlafaxine HCl 
liquisolid tablets were subjected to aging studies by storing 
nine tablets of various formulations at 30 º C/65% RH and 
40 º C/75% RH for 3 months. After this time period, samples 
were tested for their crushing strength and dissolution 
compared with the freshly tested tablets. The crushing 
strength of liquisolid formulations was affected by the 
storage at high humid conditions. Liquisolid formulations 
containing Avicel as a carrier material have shown a 
decrease in their hardness, but they still have acceptable 
hardness and can withstand handling. This decrease may be 
due to moisture sorption into cellulose structure which 
increase molecular mobility of MCC and reduce 
intermolecular attraction forces. Liquisolid formulation 
containing Eudragit RS PO as a carrier has shown an 
increase in its hardness. The glass transition temperature of 
Eudragit RS PO is 50ºC. The presence of Tween 80 may 
reduce this temperature by its plasticizing effect; hence at 
high temperature of storage, the glassy state of polymer may 
be affected, which alters the physical properties of tablets. 
Effect on hardness was most visible at 40 º C/75% RH. 
Whilst no significant difference on release rate of drug were 
visible for the same. 31  
7. CONCLUSION 
Liquisolid system provides a sleek and simple interface for 
formulation development for poorly aqueous soluble drugs. 
It is cost effective as compared to parallel solublility 
enhancement techniques. It has extensively proved itself 
feasible in dissolution enhancement, achieving zero order 
release for sustained release formulations, maintaining 
photostability of drugs, protection of natural agents from 
degradation and maintaining stability despite its internal 
humid conditions. Future prospectus lies in enhancing the 
poor compressibility and flowability of liquisolid admixtures 
along with exploration of other possible applications of the 
technique. 
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